BMP9, but not BMP10, acts as a quiescence factor on tumor growth, vessel normalization and metastasis in a mouse model of breast cancer

Tumor angiogenesis revisited: Regulators and clinical implications

(2017) Roberto Ronca et al.   MEDICINAL RESEARCH REVIEWS

Bone Morphogenetic Proteins in Vascular Homeostasis and Disease

(2017) Marie-José Goumans et al.   Cold Spring Harbor Perspectives in Biology

Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function

(2016) A. G. de Vinuesa et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

(2016) Antonio Jimeno et al.   CANCER

Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment

(2016) Jin-Sung Park et al.   CANCER CELL

A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207

(2016) Paul Wheatley-Price et al.   Journal of Thoracic Oncology

Impact of selective anti-BMP9 treatment on tumor cells and tumor angiogenesis

(2016) Verena Brand et al.   Molecular Oncology

EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance

(2016) C. Depner et al.   Nature Communications

Compound genetically engineered mouse models of cancer reveal dual targeting of ALK1 and endoglin as a synergistic opportunity to impinge on angiogenic TGF-β signaling

(2016) Nikolas M. Eleftheriou et al.   Oncotarget

Endothelial ALK1 Is a Therapeutic Target to Block Metastatic Dissemination of Breast Cancer

(2015) S. I. Cunha et al.   CANCER RESEARCH

BMP9 and BMP10 are necessary for proper closure of the ductus arteriosus

(2015) Sandrine Levet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor angiogenesis, from foe to friend

(2015) L. B. Rivera et al.   SCIENCE

Epigenetic Regulation of GDF2 Suppresses Anoikis in Ovarian and Breast Epithelia

(2015) Archana Varadaraj et al.   NEOPLASIA

Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia

(2014) Rakesh K. Jain   CANCER CELL

Molecular Pathways: Can Activin-like Kinase Pathway Inhibition Enhance the Limited Efficacy of VEGF Inhibitors?

(2014) R. S. Bhatt et al.   CLINICAL CANCER RESEARCH

BMP9 inhibits the bone metastasis of breast cancer cells by downregulating CCN2 (connective tissue growth factor, CTGF) expression

(2014) Wei Ren et al.   MOLECULAR BIOLOGY REPORTS

Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin

(2014) O E Olsen et al.   Blood Cancer Journal

BMP9 regulates cross-talk between breast cancer cells and bone marrow-derived mesenchymal stem cells

(2014) Shaoheng Wan et al.   CELLULAR ONCOLOGY

Bone morphogenetic protein 9 (BMP9) controls lymphatic vessel maturation and valve formation

(2013) S. Levet et al.   BLOOD

Context-dependent signaling defines roles of BMP9 and BMP10 in embryonic and postnatal development

(2013) H. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BMP9 and BMP10 are critical for postnatal retinal vascular remodeling

(2012) N. Ricard et al.   BLOOD

Pericyte Depletion Results in Hypoxia-Associated Epithelial-to-Mesenchymal Transition and Metastasis Mediated by Met Signaling Pathway

(2012) Vesselina G. Cooke et al.   CANCER CELL

Specificity and Structure of a High Affinity Activin Receptor-like Kinase 1 (ALK1) Signaling Complex

(2012) Sharon A. Townson et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

ALK1 as an emerging target for antiangiogenic therapy of cancer

(2011) S. I. Cunha et al.   BLOOD

Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies

(2011) Dana D. Hu-Lowe et al.   CANCER RESEARCH

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

BMP9 is produced by hepatocytes and circulates mainly in an active mature form complexed to its prodomain

(2011) Marie Bidart et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

BMP9 inhibits the proliferation and invasiveness of breast cancer cells MDA-MB-231

(2011) Ke Wang et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Bone morphogenetic protein-10 (BMP-10) inhibits aggressiveness of breast cancer cells and correlates with poor prognosis in breast cancer

(2010) Lin Ye et al.   CANCER SCIENCE

Tumor Microvasculature and Microenvironment: Novel Insights Through Intravital Imaging in Pre-Clinical Models

(2010) DAI FUKUMURA et al.   MICROCIRCULATION

ALK1-Fc Inhibits Multiple Mediators of Angiogenesis and Suppresses Tumor Growth

(2010) D. Mitchell et al.   MOLECULAR CANCER THERAPEUTICS

Bone Morphogenetic Protein-9 Is a Circulating Vascular Quiescence Factor

(2008) Laurent David et al.   CIRCULATION RESEARCH